Catalent x Novo: GLP-1 and Antitrust Concerns as Industry Reacts to the $16.5B Acquisition
What happened? Catalent, involved in producing Novo Nordisk’s top-selling GLP-1 obesity drug Wegovy, has over 50 sites globally. The acquisition follows Catalent’s strategic review due…